首页> 外文期刊>Journal of hypertension >Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk.
【24h】

Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk.

机译:盎格鲁-斯堪的纳维亚人心脏结果试验(ASCOT)中抵抗性高血压的基线预测指标:确定高危人群的风险评分。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Resistant hypertension is a well recognized clinical entity, which has been inadequately researched to date. METHODS: A multivariable Cox model was developed to identify baseline predictors of developing resistant hypertension among 3666 previously untreated Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) patients and construct a risk score to identify those at high risk. Secondary analyses included evaluations among all 19 257 randomized patients. RESULTS: One-third (1258) of previously untreated, and one-half (9333) of all randomized patients (incidence rates 75.2 and 129.7 per 1000 person-years, respectively) developed resistant hypertension during a median follow-up of 5.3 and 4.8 years, respectively. Increasing strata of baseline SBP (151-160, 161-170, 171-180, and >180 mmHg) were associated with increased risk of developing resistant hypertension [hazard ratio 1.24 (95% confidence interval, CI 0.81-1.88), 1.50 (1.03-2.20), 2.15 (1.47-3.16), and 4.43 (3.04-6.45), respectively]. Diabetes, left ventricular hypertrophy, male sex, and raised BMI, fasting glucose, and alcohol intake were other significant determinants of resistant hypertension. Randomization to amlodipine +/- perindopril vs. atenolol +/- thiazide [0.57 (0.50-0.60)], previous use of aspirin [0.78 (0.62-0.98)], and randomization to atorvastatin vs. placebo [0.87 (0.76-1.00)] significantly reduced the risk of resistant hypertension. Secondary analysis results were similar. The risk score developed allows accurate risk allocation (Harrell's C-statistic 0.71), with excellent calibration (Hosmer-Lemeshow chi statistics, P = 0.99). A 12-fold (8.4-17.4) increased risk among those in the highest vs. lowest risk deciles was apparent. CONCLUSION: Baseline SBP and choice of subsequent antihypertensive therapy were the two most important determinants of resistant hypertension in the ASCOT population. Individuals at high risk of developing resistant hypertension can be easily identified using an integer-based risk score.
机译:背景:抵抗性高血压是公认的临床实体,迄今为止尚未进行充分的研究。方法:建立了多变量Cox模型,以在3666名先前未接受治疗的盎格鲁-斯堪的纳维亚心脏预后试验(ASCOT)患者中确定发生耐药性高血压的基线预测指标,并建立风险评分以识别高危人群。次要分析包括对所有19257名随机患者的评估。结果:先前接受过治疗的患者中有三分之一(1258),随机分组的患者中有一半(9333)(每千人年分别发生率75.2和129.7)在中位随访5.3和4.8期间发生了耐药性高血压年,分别。基线SBP的层数增加(151-160、161-170、171-180和> 180 mmHg)与发生耐药性高血压的风险增加相关[危险比1.24(95%置信区间,CI 0.81-1.88),1.50( 1.03-2.20),2.15(1.47-3.16)和4.43(3.04-6.45)]。糖尿病,左心室肥大,男性,BMI升高,空腹血糖和酒精摄入是抵抗性高血压的其他重要决定因素。随机接受氨氯地平+/-培哚普利vs.阿替洛尔+/-噻嗪[0.57(0.50-0.60)],先前使用阿司匹林[0.78(0.62-0.98)]和随机分配给阿托伐他汀vs.安慰剂[0.87(0.76-1.00) ]大大降低了抵抗性高血压的风险。二级分析结果相似。制定的风险评分可以准确地进行风险分配(Harrell的C统计量为0.71),并具有出色的校准(Hosmer-Lemeshow chi统计学,P = 0.99)。在最高风险决策与最低风险决策中,风险增加了12倍(8.4-17.4)。结论:基线SBP和随后的降压治疗的选择是ASCOT人群抵抗高血压的两个最重要的决定因素。使用基于整数的风险评分,可以轻松地识别出发生耐药性高血压的高风险个体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号